Safety and Efficacy of the ANTHEM™ CR Total Knee System

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

153 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-11-23

Study Completion Date

2034-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical study will evaluate the short-term (1- and 2-year) and medium term (5-year) safety and performance of the ANTHEM™ CR Total Knee System in patients with non-inflammatory degenerative joint disease of the knee requiring total knee replacement. Clinical, radiographic, Health Economic Outcomes and safety outcomes will be evaluated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ten Year Implant Survivorship of the ANTHEM™ PS Total Knee System

NCT03078543

Arthroplasty, Replacement, Knee

ACTIVE_NOT_RECRUITING

Radiographic Migration Analysis of the ATTUNE Cementless CR Fixed-Bearing Total Knee Replacement

NCT06189872

Osteo Arthritis Knee

ACTIVE_NOT_RECRUITING NA

Safety and Efficacy of Newly Developed Knee Prosthesis for Knee Arthroplasty

NCT03184129

Knee Disease

UNKNOWN NA

A Multi-Center Study Assessing the Safety and Efficacy of the LEGION Medial Stabilized (MS) Insert in Patients Undergoing a Total Knee Arthroplasty (TKA)

NCT07199738

Inflammatory Arthritis Primary Total Knee Arthroplasty Due to Degenerative Joint Disease (Primary Diagnosis of Osteoarthritis) Post-traumatic Arthritis

NOT_YET_RECRUITING

Evaluation of the Safety and Effectiveness of the Kinamed Gem Ceramic Femoral Component for Total Knee Replacement

NCT00743717

Knee Osteoarthritis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To assess the safety and performance of the ANTHEM™ CR Total Knee System in patients with degeneration of the knee by demonstrating non-inferiority in the revision-free survival rate at 5 years compared to a literature reference rate of 96.6% (Australian Orthopaedic Association annual report 2016).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-inflammatory Degenerative Joint Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ANTHEM™ CR Total Knee System

The ANTHEM CR Total Knee System is a CE marked device. It is a cruciate retaining (CR) total knee system. It is intended to be used in patients for primary total knee replacement surgery where the posterior cruciate ligament and collateral ligaments remain intact. It is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is a candidate for primary total knee arthroplasty due to degenerative joint disease.
2. Subject is willing to sign and date an EC-approved consent form.
3. Subject has posterior cruciate ligament and all collateral ligaments intact in the index joint.
4. Subject is 18 to 75 years old at time of inclusion.
5. Subject plans to be available through ten (10) years postoperative follow-up.
6. Subject agrees to follow the study protocol.
7. Subject has achieved skeletal maturity as deemed by enrolling investigator.

Exclusion Criteria

1. Subject would receive the ANTHEM™ CR Total Knee System on the affected knee as a revision for a previously failed (TKA) or unicondylar knee arthroplasty (UKA).
2. Subject received TKA on the contralateral knee as a revision for a previously failed TKA or UKA.
3. Subject has a history of patellar fracture, patellectomy, or patello-femoral Instability.
4. Subject has inflammatory arthritis.
5. Subject possesses a contralateral or ipsilateral revision hip arthroplasty.
6. Subject has ipsilateral hip arthritis resulting in flexion contracture.
7. Subject has one or more of the following arthroplasties that are not fully healed and well-functioning, as determined by the Investigator:

* Ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing arthroplasty.
* Contralateral primary TKA or UKA.
8. Inadequate bone stock which would make the procedure unjustifiable including but not limited to: severe osteopenia/osteoporosis or family history of severe osteoporosis/osteopenia as deemed by the enrolling investigator.
9. Subject has collateral ligament insufficiency.
10. Subject has an active infection or sepsis (treated or untreated) or previous intra-articular infections.
11. Subject has presence of malignant tumor, either primary or metastatic, or benign tumor on leg with the knee to be treated.
12. Subject has conditions that may interfere with the TKA survival or outcome (e.g. Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes mellitus \[i.e. not under treatment with oral/injectable medications to control blood glucose levels\], fibromyalgia, moderate to severe renal insufficiency or neuromuscular disease).
13. Subject has contralateral lower extremity condition causing abnormal ambulation (e.g. ankle fusion, ankle arthroplasty, previous hip fracture).
14. Women who are pregnant, nursing, or of child-bearing potential who are not utilizing highly effective birth control measures.
15. Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study, including mental illness, mental retardation, drug or alcohol abuse.
16. Participation in the treatment period of another clinical trial within thirty (30) days of Visit 1.
17. Any subject that meets the definition of a Vulnerable Subject per ISO14155:2011: individual whose willingness to volunteer in a clinical investigation could be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No